Cas:139909-17-4 1-(3-fluorophenyl)pyrrolidine manufacturer & supplier

Chemical Name:1-(3-fluorophenyl)pyrrolidine

CAS.NO:139909-17-4

Synonyms:Pyrrolidine,1-(3-fluorophenyl)

Molecular Formula:C₁₀H₁₂FN

Molecular Weight:165.20700

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:3.24000

Exact Mass:165.09500

LogP:2.49090

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like Pyrrolidine,1-(3-fluorophenyl) chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Pyrrolidine,1-(3-fluorophenyl) physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Pyrrolidine,1-(3-fluorophenyl) Use and application,Pyrrolidine,1-(3-fluorophenyl) technical grade,usp/ep/jp grade.

Related News: The Company��s immuno-regulatory product candidates include ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA. 1-(3-fluorophenyl)pyrrolidine manufacturer The Company��s immuno-regulatory product candidates include ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA. 1-(3-fluorophenyl)pyrrolidine supplier Further research on Oligomannate��s pharmacological mechanism and long-term safety and effectiveness is required, according to the NMPA statement. 1-(3-fluorophenyl)pyrrolidine vendor J&J, in a statement, confirmed that the FDA authorized the two batches, but did not acknowledge the doses regulators decided should be tossed. 1-(3-fluorophenyl)pyrrolidine factory The Company��s immuno-regulatory product candidates include ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA.